Value of biomarker-based diagnostic test in differential diagnosis of hemorrhagic-ischemic stroke

Bratislava Medical Journal

Volumn 112, Issue 7, 2011, Pages 398-401

  Kavalci, C ^a   Genchallac, H ^b   Durukan, P ^c   Cevik, Y ^d  

^a TRAKYA UNIVERSITY   (Turkey)

^b TRAKYA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^d ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Biomarkers; Emergency; Stroke

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; GELATINASE B; PROTEIN S 100;

AGED; ARTICLE; BLOOD; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MALE; MIDDLE AGED; STROKE;

AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; S100 PROTEINS; STROKE;

EID: 79960548208     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Montaner J, Perea-Gainza M, Delgado P, et al. Etiologic diagno sis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008; 39: 2280-2287.
2. Hankey G, Warlow C. Treatment and secondary prevention of stro ke: evidence, costs, and effects on individuals and populations. Lancet 1999; 354: 1457-1463.
3. Fiebach JB, Schellinger PD, Jansen O, et al. CT and diffusion-weighted MR imaging in randomized order: diffusion-weighted ima ging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke 2002; 33; 2206-2210.
4. Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke 2004; 35: 57-63.
5. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC. Clinical usefulness of a biomarker-based diagnostic test for acute stroke. Stroke 2009; 40: 77-85.
6. Herrmann M, Vos P, Wunderlich MT, de Bruijn CHMM, Lamers KJB. Release of glial tissue-spesific proteins after acute stroke. Stroke 2000; 31: 2670-2677.
7. Montaner J, Alvarez-Sabin J, Molina CA, et al. Matrix metallo-proteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001; 32: 2762-2767.
8. Barber M, Langhorne P, Rumley A, Lowe GDO, Stott DJ. D-Dimer predicts early clinical progression in ischemic stroke. Stroke 2006; 37: 1113-1115.
9. Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum SlOOb levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007; 38: 2491-2495.
10. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal is-chemia in rats. Stroke 1998; 29: 1020-1030.
11. Kelly PJ, Morrow JD, Ning MM, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke. Stroke 2008; 39: 100-104.
12. Abboud H, Labreuche J, Meseguer E, et al. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007; 23: 216-220.
13. Reynolds MA, Kirchick HJ, Dahlen JR, et al. Early biomarkers of stroke. Clm Chem 2003; 49: 1733-1739.
14. Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke 2007; 38: 1873-1880.
15. Bhaatia RS, Garg RK, Gaur SP, et al. Predictive value of routine hematological and biochemical parameters on 30-day fatality in acute stroke. Neurology India 2004; 52: 220-223.
16. Hanley D. Review of critical care and emergency approaches to stroke. Stroke 2003; 34: 362-364.
17. Kent D Ruthazer R Selker H. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke 2003; 34: 464-467.
18. Schellinger P, Fiebach J, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 2003; 34: 575-583.
19. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24: 35-41
20. Montaner J, Alvarez-Sabin J, Molina C, et al. Matrix metalloproteinase expression after human cardioembolic stroke. Stroke 2001; 32: 1759-1766
21. Castellanos M, Sobrino T, Millan M, et al. Serum cellular fibronectm and matrix Metalloprotemase -9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute yschemic stroke. Stroke 2007; 38: 1855-1859.
22. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Stroke 1998; 1020-1030.